PR Newswire
25 May 2023, 11:51 GMT+10
SUZHOU, China, May 25, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial in Australia. The trial will be a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-201 in healthy adults.
AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1, stabilizing the self-inhibitory conformation of the pseudo kinase domain on the kinase domain, thereby inhibiting the function of TYK2/JAK1 kinase. It demonstrated significant efficacy in multiple animal models of diseases, including psoriasis, and is intended for the treatment of psoriasis and other inflammatory and autoimmune diseases. As an oral drug candidate, AC-201 may provide convenience and efficacy with good safety for psoriasis patients.
Dr. Xiaohu Zhang, Co-founder and CEO of Accropeutics Bioscience, said: "AC-201 is the third oral small molecule drug candidate developed by Accropeutics Bioscience to enter the clinical stage. Our company has obtained three clinical approvals this year and five since December 2021. We are committed to advancing these programs and aspire to bring relief to patients globally through these drug candidates ."
About Accropeutics Bioscience
Accropeutics Bioscience is a clinical-stage biotech company with a core focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases. The company has developed a robust portfolio of innovative compounds in various stages of development, spanning from lead optimization to clinical trials. RIPK1 inhibitor AC-003 was approved for clinical testing by FDA and NMPA in December 2021 and August 2022, respectively. The phase I trial of AC-003 is wrapping up and a phase Ib-II trial is planned for aGVHD. In the Phase I study, AC-003 was rapidly absorbed in the gastrointestinal tract after oral administration, with a peak time of 1-2 hours. The peak concentration and exposure increased linearly for the 10-480 mg dose groups, and there was no drug accumulation after multiple dose administration. Pharmacokinetic parameters supported a once-daily dosing regimen. AC-003 was well tolerated with only grade 1 adverse events reported in the Chinese (Chinese, ethnic) and US (Caucasian, African-American, Asian) participants. RIPK2 inhibitor AC-101 was approved by HREC in March 2023 and is currently in Phase I in Australia. AC-201, a selective TYK2/JAK1 inhibitor with huge potential for treating inflammatory and autoimmune diseases, was approved by HREC in May 2023 and is scheduled to launch clinical trial in Australia in the near future. The company has multiple compounds in PCC and preclinical stages. Accropeutics Bioscience owns global rights of all its assets with more than 10 patents issued in China, Japan, Korea, US and EU.
Media Contact: Jie Xu, jie.xu@accro.com.cn
Get a daily dose of Malaysia Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Malaysia Sun.
More InformationKATHMANDU, Nepal - For the past three days, agitated students and guardians have been protesting against the school administration at ...
LAHORE, Pakistan - On Thursday, anti-corruption officials arrested Pakistan Tehreek-e-Insaf (PTI) President Parvez Elahi near his Lahore residence. Anti-corruption staff ...
YANGON, Myanmar - Opium cultivation in military-ruled Myanmar increased 33% last year, reversing a six-year downward trend, according to a ...
NEW DELHI, India - Nepal's Prime Minister Pushpa Kamal Dahal met with Indian counterpart Narendra Modi at Hyderabad House in ...
SAGAING, Myanmar - According to a local resistance group leader in Sagaing Region's Ayadaw Township, a woman was captured and ...
DHAKA, Bangladesh - The Anti-Corruption Commission (ACC) has filed a case against 13 members of Grameen Telecom's board of directors, ...
BEIJING, China: On his return to China after a three year absence, which is his company's largest production hub, Tesla ...
NEW YORK, New York - U.S. stocks surged on Friday on the debt ceiling resolution and a strong jobs report.Nonfarm ...
SANTA CLARA, California: As investors piled more capital into Nvidia, the chipmaker that has become one of the biggest winners ...
PARIS, France: France has celebrated the groundbreaking for the first of four battery manufacturing gigafactories, which European and Asian companies ...
DUBLIN, Ireland: Ireland saw a 20.0 percent increase in people arriving from overseas in April 2023, compared to April 2022, ...
NEW DELHI, India: Indian federal police documents indicate that the country has filed a graft case against the UK's BAE ...